Miracor receives $3.5 million cash infusion to begin pivotal clinical “RAMSES” trial of its PICSO system, designed to improve myocardial perfusion following primary PCI. “One in three heart attack patients has impaired blood flow even after coronary angioplasty, increasing the risk of death within one year by almost 300 percent. PICSO is designed to help these at-risk patients,” Jon H. Hoem, CEO, Miracor Medical Systems and member of CEO-CF. Click here to read more…